October 01, 2024

Ocular Side Effects of Systemic Chemotherapy Agents

Systemic chemotherapy is the most common method of treatment for cancer. Newer antineoplastic agents offer improved survival rates for aggressive malignancies; however, in some cases they may cause ocular side effects. This article aims to review the various ocular effects of several classes of systemic chemotherapy drugs, including immune checkpoint inhibitors (ICIs), ALK inhibitors, MEK inhibitors, BRAF inhibitors, and EGFR inhibitors. 

New Retinal Physician

October 01, 2024

Industry Insider: Apellis Pharmaceuticals' Dr. Phil Ferrone

Phil Ferrone, MD, chief medical retina advisor, at Apellis Pharmaceuticals discusses how he got started in this role, why he moved in this direction with his career and how, the latest developments at Apellis, and more.

Ophthalmology Management

October 01, 2024

Ocular Side Effects of Systemic Chemotherapy Agents

Systemic chemotherapy is the most common method of treatment for cancer. Newer antineoplastic agents offer improved survival rates for aggressive malignancies; however, in some cases they may cause ocular side effects. This article aims to review the various ocular effects of several classes of systemic chemotherapy drugs, including immune checkpoint inhibitors (ICIs), ALK inhibitors, MEK inhibitors, BRAF inhibitors, and EGFR inhibitors. 

Retinal Physician

September 27, 2024

Cisplatin Shortage Led to Treatment Alternatives for Head and Neck Cancer, Significantly Increasing Cost

The alternative use of the monoclonal antibody cetuximab during the shortage of cisplatin in the treatment of head and neck cancer resulted in a 16% total cost increase, according to the results of a ...

The ASCO Post

September 27, 2024

CABINET Trial Supports Multitargeted Tyrosine Kinase Inhibitor for Advanced Neuroendocrine Tumors

The multicenter phase III CABINET trial has shown significantly improved progression-free survival with the multitargeted tyrosine kinase inhibitor cabozantinib vs placebo in previously treated patien...

The ASCO Post

September 27, 2024

Olanzapine May Reduce Chemotherapy-Induced Nausea and Improve Quality of Life Among Patients With Cancer

Researchers have examined whether olanzapine may be effective in controlling severe nausea and improving the quality of life in patients with cancer undergoing treatment with chemotherapy, according t...

The ASCO Post

September 27, 2024

Datopotamab Deruxtecan vs Docetaxel in Previously Treated Advanced or Metastatic NSCLC

As reported in the Journal of Clinical Oncology by Ahn et al, the phase III TROPION-Lung01 trial showed significantly improved progression-free survival—but not overall survival—with datopotamab derux...

The ASCO Post

September 27, 2024

FDA Approves Selpercatinib for RET Fusion–Positive Medullary Thyroid Cancer

On September 27, 2024, the U.S. Food and Drug Administration granted traditional approval to selpercatinib (Retevmo) for adult and pediatric patients aged 2 years and older with advanced or metastatic...

The ASCO Post

September 26, 2024

Overall Survival Results With Pembrolizumab and Chemoradiotherapy in Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer

As reported in The Lancet by Lorusso et al, overall survival results from the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial indicated a significant benefit for pembrolizumab vs placebo with concurre...

The ASCO Post